A61K31/201

NUTRITIONAL COMPOSITION USEFUL IN THE TREATMENT OF IBD PATIENTS

Compositions and methods are provided that are useful in the treatment of inflammatory bowel disease (IBD) patients. The Compositions and methods are suitable in the prevention or postponement of a relapse in inflammatory bowel disease patients.

NUTRITIONAL COMPOSITION USEFUL IN THE TREATMENT OF IBD PATIENTS

Compositions and methods are provided that are useful in the treatment of inflammatory bowel disease (IBD) patients. The Compositions and methods are suitable in the prevention or postponement of a relapse in inflammatory bowel disease patients.

Medicinal skin protection composition with an active ingredient combination which improves the skin barrier

A medicinal skin protection composition is disclosed with an active ingredient combination that specifically serves to care for aging skin that is exposed to difficult environmental conditions. The active ingredient combination obligatorily includes the components almond oil, linseed oil fatty acids, amino acids, and creatine. The medicinal skin protection composition can be used for aging skin in the form of creams, lotions etc., and also for a variety of incontinence articles, such as sanitary towels or nappies.

Medicinal skin protection composition with an active ingredient combination which improves the skin barrier

A medicinal skin protection composition is disclosed with an active ingredient combination that specifically serves to care for aging skin that is exposed to difficult environmental conditions. The active ingredient combination obligatorily includes the components almond oil, linseed oil fatty acids, amino acids, and creatine. The medicinal skin protection composition can be used for aging skin in the form of creams, lotions etc., and also for a variety of incontinence articles, such as sanitary towels or nappies.

LONG-CHAIN POLYUNSATURATED FATTY-ACID-CONTAINING FAT AND FOOD CONTAINING SAME

The present invention addresses the problem of providing a versatile, flavorful long-chain polyunsaturated fatty-acid-containing fat having exceptional oxidation stability, and a food that utilizes the fat. The problem can be solved by a long-chain polyunsaturated fatty-acid-containing fat having a specific linoleic acid content and a specific tocopherol-tocotrienol content, the fat containing a fatty acid having five or more double bonds.

LONG-CHAIN POLYUNSATURATED FATTY-ACID-CONTAINING FAT AND FOOD CONTAINING SAME

The present invention addresses the problem of providing a versatile, flavorful long-chain polyunsaturated fatty-acid-containing fat having exceptional oxidation stability, and a food that utilizes the fat. The problem can be solved by a long-chain polyunsaturated fatty-acid-containing fat having a specific linoleic acid content and a specific tocopherol-tocotrienol content, the fat containing a fatty acid having five or more double bonds.

PREPARATION METHOD OF A COLLOIDAL SYSTEM OF STABILISATION AND CONTROLLED RELEASE OF ROYAL JELLY COMPONENTS FOR VARIOUS USES
20230190635 · 2023-06-22 · ·

A preparation method of a colloidal system of stabilisation and controlled release of royal jelly ingredients, wherein the system is characterized by the extraction of the components of the royal jelly and the simultaneous encapsulation in combinatorial liposome -cyclodextrin carriers for achieving controlled release, taking advantage of the special features of both carriers, namely: the ability of cyclodextrins to encapsulate polyphenols and their enhanced skin penetration ability as well as the ability of liposomes in encapsulating large amounts of components of various degrees of polarity, for local component transport and for controlled release rate.

USE OF METABOLIC REGULATORS FOR THE TREATMENT OF COVID-19

Methods of treating coronavirus infection, or decreasing the risk of symptomatic infection, by administering a peroxisome proliferator-activated receptor alpha (PPARA) agonist or an inositol-requiring enzyme 1 (IRE1) pathway inhibitor are provided.

USE OF METABOLIC REGULATORS FOR THE TREATMENT OF COVID-19

Methods of treating coronavirus infection, or decreasing the risk of symptomatic infection, by administering a peroxisome proliferator-activated receptor alpha (PPARA) agonist or an inositol-requiring enzyme 1 (IRE1) pathway inhibitor are provided.

NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS
20220378734 · 2022-12-01 ·

Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.